| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14712598.2017.1279601 |
| P698 | PubMed publication ID | 28064543 |
| P50 | author | Swaroop Hassan Suresh | Q61160014 |
| P2093 | author name string | Sunil Dogra | |
| Shraddha Uprety | |||
| P2860 | cites work | Relevance of CD6-mediated interactions in T cell activation and proliferation | Q24300571 |
| Definition of treatment goals for moderate to severe psoriasis: a European consensus | Q24604445 | ||
| Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies | Q26764867 | ||
| Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab | Q33573621 | ||
| Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. | Q34478064 | ||
| Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study | Q35139830 | ||
| German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). | Q35875481 | ||
| Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction | Q35943010 | ||
| The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. | Q36602668 | ||
| Pathogenesis and therapy of psoriasis | Q36742020 | ||
| A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis | Q37390483 | ||
| Treating moderate to severe psoriasis - best use of biologics | Q38174153 | ||
| Secukinumab for treating plaque psoriasis | Q38636359 | ||
| The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations | Q38722598 | ||
| Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases | Q38730494 | ||
| 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland | Q42732008 | ||
| Psoriasis prevalence among adults in the United States | Q46308366 | ||
| Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study | Q48008926 | ||
| Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). | Q51075376 | ||
| CD6: expression during development, apoptosis and selection of human and mouse thymocytes. | Q53969369 | ||
| Psoriasis | Q56115292 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 395-402 | |
| P577 | publication date | 2017-01-09 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis | |
| P478 | volume | 17 |
| Q57816679 | Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells |
| Q93052101 | Overexpression of CD6 and PD-1 Identifies Dysfunctional CD8+ T-Cells During Chronic SIV Infection of Rhesus Macaques |
| Q64069190 | Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India |
| Q52689322 | Targeting CD6 for the treatment of experimental autoimmune uveitis. |
| Q104283080 | Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab |
Search more.